Oncology

Swiss antibody-drug conjugate CDMOs sit on a market projected to hit $15.4B in 2026. Here is how Cerbios, Lonza, ADC Therapeutics and Araris compete.

Egypt's first EU-GMP oncology complex runs 22 million units a year. Where the high-containment equipment RFQs sit and who issues them.